BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
about
The value of trabectedin in the treatment of soft tissue sarcomaActivity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomasHallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application.Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model
P2860
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
@ast
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
@en
type
label
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
@ast
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
@en
prefLabel
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
@ast
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
@en
P2093
P2860
P356
P1476
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
@en
P2093
A Italiano
A Laroche-Clary
A Neuville
F Bertucci
V Le Morvan
P2860
P2888
P304
P356
10.1038/BJC.2014.624
P407
P577
2015-01-20T00:00:00Z